Patricia L Allen
CIK 1348587 · Chief Financial Officer · last filed 2026-06-17
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
DCPH price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
200 SMITH STREET
WALTHAM, MA 02451
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ZBIO | Director | 19,860 | $27.24 | $541.0K | $499.7K | 4 | 2026-06-17 |
| Deciphera Pharmaceuticals, Inc. (DCPH) Delisted | Director | 0 | $25.59 | $0 | -$2.34M | 13 | 2024-06-11 |
| KINETA, INC./DE (YMTX) Delisted | Director | — | $13.23 | — | $0 | 2 | 2021-06-04 |
| Larimar Therapeutics, Inc. (ZFGN) Delisted | Chief Financial Officer | 1,649 | — | — | $49.9K | 6 | 2019-01-24 |
| ALNY | VP of Finance and Treasurer | 26,165 | $227.66 | $5.96M | -$1.08M | 7 | 2010-12-10 |
Recent Filings · Page 3 of 4
32 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2017-10-02 | Deciphera Pharmaceuticals, Inc. (DCPH) Delisted | Exer (M) | — | $0 | EDGAR |
| 2017-01-31 | Larimar Therapeutics, Inc. (ZFGN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2016-07-26 | Larimar Therapeutics, Inc. (ZFGN) Delisted | Buy (P) | +16,000 | $49.9K | EDGAR |
| 2016-04-04 | Larimar Therapeutics, Inc. (ZFGN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2015-03-03 | Larimar Therapeutics, Inc. (ZFGN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2010-12-10 | ALNY | Grant (A) | — | $0 | EDGAR |
| 2009-12-11 | ALNY | Grant (A) | — | $0 | EDGAR |
| 2009-04-24 | ALNY | Mixed | — | -$417.0K | EDGAR |
| 2008-12-11 | ALNY | Grant (A) | — | $0 | EDGAR |
| 2007-12-14 | ALNY | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.